Dosage regimen for a S1P receptor agonist

Details for Australian Patent Application No. 2009330176 (hide)

Owner Novartis AG

Inventors Schmouder, Robert; Dumortier, Thomas; David, Olivier; Looby, Michael

Agent Davies Collison Cave

Pub. Number AU-A-2009330176

PCT Pub. Number WO2010/075239

Priority 61/139,672 22.12.08 US; 61/218,530 19.06.09 US; 61/246,715 29.09.09 US

Filing date 21 December 2009

Wipo publication date 1 July 2010

International Classifications

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

Event Publications

7 July 2011 PCT application entered the National Phase

  PCT publication WO2010/075239 Priority application(s): WO2010/075239

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009330178-Zymomonas with improved xylose utilization in stress conditions for the production of ethanol

2009330175-Human CGRP receptor binding proteins